亚宝药业(600351) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥569,303,758.32, a decrease of 16.01% compared to the same period last year[2] - Total profit for the quarter was ¥40,933,824.50, down 42.51% year-on-year[2] - Net profit attributable to shareholders was ¥40,697,053.18, reflecting a decline of 26.22% compared to the previous year[2] - The company reported a decrease of 30.84% in net profit after deducting non-recurring gains and losses due to the termination of the SY009 R&D project[7] - The basic earnings per share for the quarter was ¥0.0583, down 24.23% year-on-year[2] - Total revenue for the first three quarters of 2025 was CNY 1,708,712,223.13, a decrease of 19.4% compared to CNY 2,121,509,818.79 in the same period of 2024[16] - Net profit for the first three quarters of 2025 was CNY 198,491,469.17, down 13.1% from CNY 228,467,854.51 in the same period of 2024[18] - Earnings per share for the first three quarters of 2025 was CNY 0.3066, compared to CNY 0.3241 in 2024, reflecting a decrease of 5.5%[18] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 221.16% to ¥129,363,179.19[2] - Cash and cash equivalents increased to ¥645,407,882.65 from ¥578,594,453.98, reflecting a growth of approximately 11.43%[13] - Total current assets decreased to ¥1,484,605,647.29 from ¥1,559,311,767.72, a decline of about 4.79%[13] - Cash inflow from sales of goods and services was $1.64 billion, compared to $1.84 billion in the previous period, reflecting a decrease of 11.1%[21] - Total cash outflow from operating activities was $1.30 billion, down from $1.52 billion in the previous period, indicating a reduction of 14.4%[21] - Cash received from investment recoveries was $144.77 million, a significant increase from $4.87 million in the previous period[22] - Cash paid for fixed assets and intangible assets was $38.77 million, compared to $28.32 million in the previous period, representing an increase of 36.8%[22] Shareholder Information - Total shareholders at the end of the reporting period reached 53,669[9] - The largest shareholder, Shanxi Yabao Investment Group Co., Ltd., holds 94,300,000 shares, accounting for 13.47% of total shares[9] - The top ten shareholders do not have any related party relationships or concerted actions among them[11] - The company has not reported any significant changes in the participation of major shareholders in securities lending or borrowing activities[11] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,342,721,351.58, a decrease of 5.68% from the end of the previous year[3] - The equity attributable to shareholders decreased by 3.35% to ¥2,795,760,982.69[3] - Total liabilities decreased to CNY 585,773,356.92 from CNY 649,023,044.55, a reduction of 9.8%[15] - Non-current assets totaled CNY 1,858,115,704.29, down from CNY 1,984,630,806.62, indicating a decrease of 6.4%[15] Operating Costs and Expenses - Total operating costs for the first three quarters of 2025 were CNY 1,422,105,604.68, down from CNY 1,854,942,934.53 in 2024, reflecting a reduction of 23.3%[16] - Operating profit for the first three quarters of 2025 was CNY 253,258,850.67, compared to CNY 288,373,771.98 in 2024, indicating a decline of 12.2%[17] - The company reported a significant reduction in sales expenses, which were CNY 327,463,027.22 in 2025 compared to CNY 514,819,616.99 in 2024, a decrease of 36.3%[17] - Research and development expenses for the first three quarters of 2025 were CNY 72,291,467.66, down from CNY 89,911,769.62 in 2024, reflecting a decrease of 19.7%[17]